PACB vs RSMDF
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PACB is a Hold and RSMDF is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PACB’s FA Score shows that 0 FA rating(s) are green whileRSMDF’s FA Score has 1 green FA rating(s).
- PACB’s FA Score: 0 green, 5 red.
- RSMDF’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PACB’s TA Score shows that 6 TA indicator(s) are bullish.
- PACB’s TA Score: 6 bullish, 3 bearish.
Price Growth
PACB (@Medical Specialties) experienced а -15.81% price change this week, while RSMDF (@Medical Specialties) price change was -1.62% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -4.22%. For the same industry, the average monthly price growth was +1.48%, and the average quarterly price growth was +1.33%.
Reported Earning Dates
PACB is expected to report earnings on Feb 13, 2025.
RSMDF is expected to report earnings on Jan 23, 2025.
Industries' Descriptions
@Medical Specialties (-4.22% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| PACB | RSMDF | PACB / RSMDF | |
| Capitalization | 977M | 32.7B | 3% |
| EBITDA | -277.28M | 1.31B | -21% |
| Gain YTD | -79.918 | 54.164 | -148% |
| P/E Ratio | N/A | 37.59 | - |
| Revenue | 201M | 4.02B | 5% |
| Total Cash | 631M | 228M | 277% |
| Total Debt | 934M | 1.72B | 54% |
PACB | RSMDF | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 74 | 90 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 99 Overvalued | 18 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 60 | |
SMR RATING 1..100 | 97 | 41 | |
PRICE GROWTH RATING 1..100 | 46 | 37 | |
P/E GROWTH RATING 1..100 | 83 | 56 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RSMDF's Valuation (18) in the null industry is significantly better than the same rating for PACB (99) in the Biotechnology industry. This means that RSMDF’s stock grew significantly faster than PACB’s over the last 12 months.
RSMDF's Profit vs Risk Rating (60) in the null industry is somewhat better than the same rating for PACB (100) in the Biotechnology industry. This means that RSMDF’s stock grew somewhat faster than PACB’s over the last 12 months.
RSMDF's SMR Rating (41) in the null industry is somewhat better than the same rating for PACB (97) in the Biotechnology industry. This means that RSMDF’s stock grew somewhat faster than PACB’s over the last 12 months.
RSMDF's Price Growth Rating (37) in the null industry is in the same range as PACB (46) in the Biotechnology industry. This means that RSMDF’s stock grew similarly to PACB’s over the last 12 months.
RSMDF's P/E Growth Rating (56) in the null industry is in the same range as PACB (83) in the Biotechnology industry. This means that RSMDF’s stock grew similarly to PACB’s over the last 12 months.
| PACB | |
|---|---|
| RSI ODDS (%) | N/A |
| Stochastic ODDS (%) | 2 days ago 89% |
| Momentum ODDS (%) | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 81% |
| TrendWeek ODDS (%) | 2 days ago 89% |
| TrendMonth ODDS (%) | 2 days ago 85% |
| Advances ODDS (%) | 9 days ago 84% |
| Declines ODDS (%) | 6 days ago 88% |
| BollingerBands ODDS (%) | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 89% |
PACB and
Correlation & Price change
A.I.dvisor indicates that over the last year, PACB has been loosely correlated with AZTA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if PACB jumps, then AZTA could also see price increases.
| Ticker / NAME | Correlation To PACB | 1D Price Change % | ||
|---|---|---|---|---|
| PACB | 100% | -3.90% | ||
| AZTA - PACB | 46% Loosely correlated | +4.09% | ||
| MASS - PACB | 44% Loosely correlated | -5.58% | ||
| TWST - PACB | 41% Loosely correlated | -0.06% | ||
| HBIO - PACB | 41% Loosely correlated | +1.40% | ||
| BIO - PACB | 40% Loosely correlated | -1.49% | ||
More | ||||
RSMDF and
Correlation & Price change
A.I.dvisor tells us that RSMDF and NAOV have been poorly correlated (+30% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that RSMDF and NAOV's prices will move in lockstep.
| Ticker / NAME | Correlation To RSMDF | 1D Price Change % | ||
|---|---|---|---|---|
| RSMDF | 100% | +0.63% | ||
| NAOV - RSMDF | 30% Poorly correlated | +5.30% | ||
| PODD - RSMDF | 25% Poorly correlated | -0.81% | ||
| ANIK - RSMDF | 25% Poorly correlated | -1.89% | ||
| FLGT - RSMDF | 25% Poorly correlated | -1.12% | ||
| PACB - RSMDF | 24% Poorly correlated | -3.90% | ||
More | ||||